SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a critical milestone signifying the company's transition toward commercial scalability for direct-to-device broadband. The community is buzzing with excitement, anticipating significant future growth and contract announcements, though some express caution regarding valuation and a potential "sell the news" reaction. This event firmly positions ASTS as a major player in the rapidly evolving space-based cellular network industry.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is a major talking point with significant anticipation surrounding its upcoming showcases of commercial quantum computing solutions at industry events. The community is deeply divided, with many optimistic about the company's potential for broad adoption and future partnerships, while a vocal segment expresses caution regarding valuation and recent executive stock sales. This reflects broader market debate on the commercial readiness and investment risks within the evolving quantum computing sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is a major talking point following its announced inclusion in the S&P MidCap 400. This news is generating significant community excitement, anticipating increased institutional demand, enhanced visibility, and a potential short squeeze. Investors are highlighting its strong financial position and its critical role in the rapidly evolving agentic AI and automation sector as key drivers for future growth.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending on widespread anticipation for the FDA's decision on Narsoplimab, a first-in-class drug for TA-TMA, with many speculating on an early approval before the December 26th PDUFA date. The community is actively discussing potential for a significant price surge fueled by high unmet medical need, strong trial data, and the recent $2.1 billion Novo Nordisk deal that has bolstered Omeros's financial position. This binary event has triggered intense debate over short manipulation and a possible "shakeout" of shares ahead of what many believe will be a transformative approval.

Starfighters Space Inc

Starfighters Space Inc. (FJET), a recently public aerospace company, is trending due to extreme volatility driven by its low float and very high short interest. The community is fiercely divided, with many anticipating a significant short squeeze while others label it a pump-and-dump. There is widespread discussion about alleged market manipulation influencing its price action amidst this speculative fervor.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending following its acquisition by Sanofi, prompting widespread congratulatory messages among shareholders and discussions around the valuation of the deal. The acquisition, which enhances Sanofi's vaccine portfolio with Dynavax's Hepatitis B vaccine and shingles treatment, also fuels conversations regarding the implications for Vaxart due to their oral COVID-19 vaccine licensing agreement. This development provides a significant exit for long-term investors amid prior frustrations concerning management and shareholder value.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid mixed signals, with community frustration mounting over its stock performance despite positive developments. While initial discussion revolved around rumors of Nvidia abandoning Intel's 18A process, the recent clearance of Nvidia's $5 billion investment in Intel and the company's partnership in the US Department of Energy's "Genesis Mission" for AI are fueling optimism among long-term bulls regarding its advanced foundry initiatives and US government support.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is trending due to multiple strategic partnerships focused on deploying its advanced thin-film solar technology across aerospace, defense, and terrestrial applications. The community is actively discussing the stock's significant price and volume surges, viewing it as a high-potential speculative play driven by the burgeoning space economy and demand for resilient power in extreme environments.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing significant buzz driven by substantial new orders for its 800G transceivers from hyperscale customers, positioning the company as a key enabler in the expanding AI-driven data center market. The community is actively discussing strong bullish signals, including notable institutional interest and positive analyst upgrades, with many anticipating a significant long-term growth trajectory for its high-speed optical solutions. This strong momentum highlights AAOI's critical role in supporting the next generation of AI infrastructure amid broader sector growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BIOA With Ventyx positive results of it cardiometabolic drug in phase 2, BIOA had a &quot;NLRP3 inhibitor success&quot; rally for about 30%. Most missed the fact that Ventyx was also measuring weigh loss benefit, which was not observed in this phase 2 study but the company was enthusiastic about due to its preclinical results yielding weigh loss and lean mass relative maintenance.  
BIOA has the same opinion and its preclinical results purportedly for BGE 102 data showed powerful weight reduction both as monotherapy and in combo with GLP1. 
Ventyx CEO in the conference after the results did state that this study puts to rest the theory that NLRP3 pathway can reduce the weight. But VTYX was also measuring inflammation reduction so at least that link was proven. Problem with BIOA is that it classifies its study as Obesity drug. In fact with Ventyx its price should have gone down a bit as BGE 102 is the most advanced drug in the pipeline. Unless they have a differentiated drug in some specific way.

StockTwits Web

BioAge Labs Inc.

 With Ventyx positive results of it cardiometabolic drug in phase 2, BIOA had a "NLRP3 inhibitor success" rally for about 30%. Most missed the fact that Ventyx was also measuring weigh loss benefit, which was not observed in this phase 2 study but the company was enthusiastic about due to its preclinical results yielding weigh loss and lean mass relative maintenance.  
BIOA has the same opinion and its preclinical results purportedly for BGE 102 data showed powerful weight reduction both as monotherapy and in combo with GLP1. 
Ventyx CEO in the conference after the results did state that this study puts to rest the theory that NLRP3 pathway can reduce the weight. But VTYX was also measuring inflammation reduction so at least that link was proven. Problem with BIOA is that it classifies its study as Obesity drug. In fact with Ventyx its price should have gone down a bit as BGE 102 is the most advanced drug in the pipeline. Unless they have a differentiated drug in some specific way.

VMST1

Like BIOA, NMRA benefited from Ventyx news of NLPR3 pathway success as a new class of drug. However, Both BIOA and NMRA are trying to promote their NLRP drugs as weight loss (obseity) reduction drug as mere mention of the segment fuels the Biotech stocks just Like AI does for Tech stocks these days.. But as Ventyx phase 2 study indicates NLRP3 doesn&#39;t help in significant weight loss in monotherapy and in combo with GLP1, why the sudden price appreciation for BIOA and NMRA? It is taking general good indication of NLRP3 drugs and ignoring NLRP3 failure to be effective for obesity/weight loss. 
 
Perhaps, BIOA and NMRA consider their NLRP3 drugs very different from Ventyxs&#39;s. By the time their NLRP3 drug releases phase 2 results, the difference will be clear. My take is that it is a very difficult goal to achieve given what fairly advanced  first NLRP3 drug showed in phase 2 study.

Like BIOA, NMRA benefited from Ventyx news of NLPR3 pathway success as a new class of drug. However, Both BIOA and NMRA are trying to promote their NLRP drugs as weight loss (obseity) reduction drug as mere mention of the segment fuels the Biotech stocks just Like AI does for Tech stocks these days.. But as Ventyx phase 2 study indicates NLRP3 doesn't help in significant weight loss in monotherapy and in combo with GLP1, why the sudden price appreciation for BIOA and NMRA? It is taking general good indication of NLRP3 drugs and ignoring NLRP3 failure to be effective for obesity/weight loss. 
 
Perhaps, BIOA and NMRA consider their NLRP3 drugs very different from Ventyxs's. By the time their NLRP3 drug releases phase 2 results, the difference will be clear. My take is that it is a very difficult goal to achieve given what fairly advanced  first NLRP3 drug showed in phase 2 study.